openPR Logo
Press release

Zika-Vaccine Receives Boost by Innovate UK

09-07-2016 12:26 PM CET | Health & Medicine

Press release from: Themis Bioscience

/ PR Agency: PR&D
The further development of a promising Zika vaccine candidate by Themis Bioscience has received a strong support by the United Kingdom's innovation agency, Innovate UK. Themis, a Vienna-based specialist for vaccine development, will receive 1 Mio. GBP supporting the further development of this prophylactic vaccine and the conducting of a Phase 1 clinical trial.

Today, Themis Bioscience GmbH (Vienna, Austria), a company specialized in vaccine development, announced that it will receive 1 Mio. GBP in funding by the innovation agency of the United Kingdom, Innovate UK. The funds will accelerate the further development of a vaccine candidate against the Zika virus infection and its first clinical trial. The vaccine candidate is based on Themis' proprietary Themaxyn® platform that uses a well-established measles vaccine vector whose core technology has been developed at the Institut Pasteur, France.

Dr. Erich Tauber, CEO and founder of Themis welcomes the support: "We recently succeeded in quickly advancing a Chikungunya vaccine candidate into Phase 2 clinical trials and Themis demonstrated its expertise in the fast and focused development of promising vaccines. Thanks to the support of Innovate UK, we can now apply our platform technology for the further development of our prophylactic Zika vaccine candidate, which will address the worldwide emerging Zika threat."

In the past twelve months, Themis identified several suitable validated Zika antigens for the development of the vaccine. The company's team had tested a number of candidate vaccines in animal models, and has already initiated a toxicity study and GMP manufacturing. The main part of the program supported by Innovate UK is the Phase 1 clinical trial, as well as the development of a thermostable formulation for the vaccine.

One of the major advantages of the Zika vaccine candidate of Themis is a validated as well as cost-efficient production process. The measles vector technology developed by Themis forms the basis of all current vaccine candidates advanced by the company. It allows a rapid upscaling of the very cost effective vaccine production process once the vaccine candidate has been determined. This ability is critical for a vaccine that is supposed to combat diseases such as Zika from spreading in highly populated areas. Additionally, the measles vaccine has already proven its high efficacy and safety on well over a billion individuals over the last 30–40 years, and the technology offers an excellent safety profile. Under the terms of a broad license agreement with the Institut Pasteur, Themis owns the rights to use the measles vector for a wide range of indications including Chikungunya and Zika.

About Themis (September 2016):
Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Dengue. The company's highly innovative and fully patent-protected measles virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for all current vaccine candidates of the Vienna-based company.
www.themisbio.com

About the vaccine technology:
The core technology of the measles vector platform has been developed at the Institut Pasteur in Paris and is licensed to Themis. It relies on the use of the standard measles vaccine as a vaccination vector. Genes coding for selected antigens from the zika virus have been inserted into the genome of this well-established vaccine. The measles-zika vaccine delivers the zika antigens directly to macrophages and dendritic cells – the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to zika virus. This results in a powerful, antigen-focused immune response, which is most likely to confer long-term immunity as does the measles vaccine.

About Innovate UK:
Innovate UK is the UK's innovation agency. It works with people, companies and partner organisations to find and drives the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk

Contact Themis Bioscience GmbH:
Dr. Erich Tauber
CEO
Muthgasse 11/2
1190 Vienna, Austria
T +43 / 1 / 236 7151
E erich.tauber@themisbio.com
W http://www.themisbio.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Zika-Vaccine Receives Boost by Innovate UK here

News-ID: 361169 • Views: 471

More Releases from Themis Bioscience

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chiku …
A prophylactic vaccine candidate against Chikungunya fever developed with proprietary technology of Themis Bioscience GmbH will be tested in a clinical trial sponsored by the U.S. National Institutes of Health (NIH). The vaccine, developed by Themis, is based on a standard measles vaccine as a vaccination vector and hence offers an excellent safety profile. It already showed high seroconversion rates in the preceding Phase I clinical trial: 100 percent of
Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine
Themis Measles Vector Technology Central to Action Plan Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus. Supported with very substantial funding by the EU, the ZIKAVAX consortium consists of Themis, the European Vaccine Initiative, Institut Pasteur and the Commissariat à l'énergie atomique et aux énergies alternatives. Pivotal to the joint development initiative is Themis' propietary technology platform based
Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine
Themis Measles Vector Technology Central to Action Plan Vienna, 13 December 2016 – Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus. Supported with very substantial funding by the EU, the ZIKAVAX consortium consists of Themis, the European Vaccine Initiative, Institut Pasteur and the Commissariat à l'énergie atomique et aux énergies alternatives. Pivotal to the joint development initiative is
Leading Chikungunya Vaccine in Clinical Trial Phase 2
With the first patient vaccinated, a Phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally and is developed by the Austrian biotech company Themis Bioscience GmbH. It is based on the company's proprietary Themaxyn® platform, a standard measles vaccination vector developed in collaboration with the Institut Pasteur, that offers an excellent immunogenicity and

All 5 Releases


More Releases for Zika

Zika Virus Testing Market Worth US$ 4,400 Mn by 2020
The recent outbreak of Zika in Brazil and in the rest of Latin America, the Caribbean, the United States, Canada and various parts of Europe was caused by a more virulent viral strain from Asia. This has increased the rate of Zika virus tests being conducted worldwide. A new research report by Future Market Insights highlights the current as well as future scenario of the Zika virus testing market. This
Zika Virus market 2018-2025, NewLink Genetics, Intrexon, Cerus
Global Zika Virus market 2018 by ReportsQuest presents a professional and complete analysis of on the current Industry situation. The Global report includes Zika Virus Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Zika Virus market players and the future prospects from various angles in detail. Industry analysis is a assessment tool used
Global Zika Virus Market Research Report 2017
Qyresearchreports include new market research report "Global Zika Virus Market Research Report 2017" to its huge collection of research reports. The global market for Zika Virus has been marked on several factors that are on the verge or have already impacted the growth of the market in several contexts. The report further pronounces different statistics and data pertaining to the global Zika Virus market. The core aim of the report is
Global Zika Virus Market Research Report 2017
The Global Zika Virus 2017 Market Research Report is a professional and in-depth study on the current state of the Zika Virus industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Zika Virus market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well
Zika Vaccines Market - Global Industry Insights 2025
Zika vaccines are developed for immunization & prevention against diseases caused by Zika virus. This virus belongs to genus Flavivirus and is transmitted by Aedes mosquitoes. The virus can also be transmitted through blood transfusion, sexual contact or from infected pregnant women to the fetus. Diagnosis of this infection is confirmed by detecting viral DNA through PCR. However, only 1 in 4 people with zika infection are prone to develop
Zika Virus Consumption 2016 Market Research Report
Qyresearchreports include new market research report Global Zika Virus Consumption 2016 Market Research Report to its huge collection of research reports. This report is a descriptive and analytical dissemination of information in the Zika Virus, for those associated with it or those who wish to enter the market in the immediate future. The report provides – within its predetermined forecast period – the latest installment of this stream of research reports.